Company profile: Ablynx
1.1 - Company Overview
Company description
- Provider of a proprietary Nanobody® technology platform for the discovery and development of therapeutic nanobodies—small single-domain antibody fragments—targeting serious human diseases including inflammation, haematology, oncology and pulmonary disease, with approximately 25 projects in the pipeline.
Products and services
- NANOBODY® Technology Platform: Proprietary, single-domain antibody fragment system that engineers small therapeutic proteins for serious diseases—spanning inflammation, haematology, oncology, and pulmonary—enabling discovery and development of Nanobodies®
- Nanobody Discovery Programs: Targeted research programs discover small, single-domain antibody fragments (Nanobodies®) for therapeutic use across inflammation, haematology, oncology, and pulmonary disease
- Nanobody Development Pipeline: Multi-indication portfolio develops approximately 25 Nanobodies® projects into therapeutic products addressing inflammation, haematology, oncology, and pulmonary disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ablynx
Saniona
HQ: Denmark
Website
- Description: Provider of pharmaceutical research and development focused on advancing multiple potential new medicines through clinical trials and pioneering highly selective ion channel modulators, leveraging a well-established approach to disease treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Saniona company profile →
Sophos Biotech
HQ: Italy
Website
- Description: Provider of pharmaceutical medicines and drugs for the treatment of mucositis and prostate and breast oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sophos Biotech company profile →
Zealand Pharma
HQ: Denmark
Website
- Description: Provider of peptide-based medicines and novel specialty drug candidates, leveraging leading-edge expertise and partnerships. Offerings include dasiglucagon for severe hypoglycemia (with Novo Nordisk), survodutide for obesity and MASH (with Boehringer Ingelheim), dapiglutide, and devices such as the investigational bihormonal iLet bionic pancreas (with Beta Bionics) and a continuous infusion pump for congenital hyperinsulinism (with DEKA Research).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zealand Pharma company profile →
ViroPharma
HQ: United States
Website
- Description: Provider of biopharmaceutical products addressing serious diseases, focused on therapies used by physician specialists or in hospital settings; develops and commercializes treatments, with two marketed products and three development programs, including Vancocin HCl capsules.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ViroPharma company profile →
Paion
HQ: Germany
Website
- Description: Provider of biopharmaceutical products; develops and commercializes drug candidates for diseases or interventions with substantial unmet medical need. Lead compound: remimazolam, an intravenous, ultra-short-acting, controllable benzodiazepine. Portfolio: Byfavo (procedural sedation, general anesthesia); Angiotensin II/GIAPREZA (refractory hypotension in septic or distributive shock); Eravacycline/XERAVA (complicated intra-abdominal infections in adults).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paion company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ablynx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ablynx
2.2 - Growth funds investing in similar companies to Ablynx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ablynx
4.2 - Public trading comparable groups for Ablynx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →